We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MacroGenics (MGNX) Stock Jumps 6.6%: Will It Continue to Soar?
Read MoreHide Full Article
MacroGenics (MGNX - Free Report) shares rallied 6.6% in the last trading session to close at $30.19. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 36.1% gain over the past four weeks.
This marks the third consecutive trading day of MacroGenics’ price increase driven by optimism surrounding the anticipated commercial launch of the company’s first drug, MARGENZA (FDA approved in December 2020) this month. The drug paired with chemotherapy will be utilized for the treatment of adult patients (who have already received two or more prior anti-HER2 regimens of which one was for metastatic disease) with metastatic HER2-positive breast cancer. Market is also upbeat about the company’s solid revenue performance with full-year 2020 sales delivering an improvement of 63.4% from the year-ago period.
Price and Consensus
This biopharmaceutical company is expected to post quarterly loss of $0.53 per share in its upcoming report, which represents a year-over-year change of +41.8%. Revenues are expected to be $31.16 million, up 127.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For MacroGenics, the consensus EPS estimate for the quarter has been revised 15.1% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on MGNX going forward to see if this recent jump can turn into more strength down the road.
Image: Bigstock
MacroGenics (MGNX) Stock Jumps 6.6%: Will It Continue to Soar?
MacroGenics (MGNX - Free Report) shares rallied 6.6% in the last trading session to close at $30.19. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 36.1% gain over the past four weeks.
This marks the third consecutive trading day of MacroGenics’ price increase driven by optimism surrounding the anticipated commercial launch of the company’s first drug, MARGENZA (FDA approved in December 2020) this month. The drug paired with chemotherapy will be utilized for the treatment of adult patients (who have already received two or more prior anti-HER2 regimens of which one was for metastatic disease) with metastatic HER2-positive breast cancer. Market is also upbeat about the company’s solid revenue performance with full-year 2020 sales delivering an improvement of 63.4% from the year-ago period.
Price and Consensus
This biopharmaceutical company is expected to post quarterly loss of $0.53 per share in its upcoming report, which represents a year-over-year change of +41.8%. Revenues are expected to be $31.16 million, up 127.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For MacroGenics, the consensus EPS estimate for the quarter has been revised 15.1% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on MGNX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>